AlphAIAlphAI — Financial news for AI agents
investing.comOCT 213 min read$ELV

Elevance Health Q3 2026 slides: EPS beats, guidance raised to $29

Elevance Health (ELV) reported Q3 2026 adjusted EPS of $6.99, beating estimates by $2.29. Revenue was $50.4B, up 0.7% YoY. Guidance raised to $29. Shares fell 2.24% due to non-operating gains. Operating margin held at 2.7%.

Original reporting
investing.com
Published Oct 21, 2026, 1:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 2:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ELV
Bearish
high confidence
Mentioned
$ELV
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ELVBearishHigh
01

Why it matters

The earnings beat is driven by $1.85 per‑share non‑operating gains, leading to a 2.2% share decline despite strong operating performance.

02

Market read

First report of earnings and guidance raise for a large‑cap health insurer; market reaction reflects concerns over earnings quality.

03

What to watch

Potential upside from Carelon services growth and cost‑management initiatives may offset the earnings composition concerns.

Relevance 9/10Novelty 9/10Timing: after‑hours today

Background

Elevance Health reported Q3 2026 results with a 48.7% EPS beat and lifted FY guidance.

Company-level read

Ticker impact

$ELVBearishHigh confidence
Context

Q3 2026 earnings beat expectations and raised FY EPS guidance to at least $29

Expected impact

likely pressure as the market prices in the $1.85 per‑share non‑operating contribution

Evidence & confidence

The earnings beat is largely from investment income, which may not recur, prompting a sell‑off.

Market effects

Sector

Health‑care insurers may see heightened scrutiny of non‑operating items in earnings.

Regional

U.S. health‑care stocks could see modest downside pressure.

Global

Limited; impact confined to U.S. listed health‑care sector.

Counterpoint

What could challenge this read

The EPS beat and raised guidance could support a short‑term bounce if investors discount the non‑operating items.

Key entities

  • company
    Elevance Health

    U.S. health‑care insurer (NYSE:ELV) reporting Q3 2026 earnings.

Read at source← All news

StoryElevance Health posts Q3 2026 earnings beat and lifts FY 2026 EPS and cash‑flow guidance

Also covered by

4 outlets

Related articles

OCT 21
$ELVMed

What Elevance Health (ELV) Said on Its Q3 Earnings Call

Elevance Health (ELV) updated its full-year Medicaid operating margin outlook, expecting slight improvements ahead of prior estimates. The company anticipates margins to recover in 2027 due to better rate alignment and cost-management initiatives. Medicare Advantage and ACA results support guidance, with expectations of at least 2% operating margin for Medicare Advantage and modestly higher ACA margins. CarelonRx reported 10.8% operating gain growth and a 5.3% operating margin.

finance.yahoo.com3 min
OCT 21
$TSLAMed

Nasdaq futures lead gains as SpaceX, Super Micro results lift AI trade

Nasdaq futures rose on Wednesday, led by gains in SpaceX (up 7.2%) and Super Micro (up 10.9%) after their earnings reports. SpaceX posted its first profit as a public company, while Super Micro exceeded revenue and profit margin estimates. Tesla (up 1.4%) also gained after Elon Musk suggested a potential merger with SpaceX. Netflix fell 6.6% after issuing a weaker-than-expected forecast. Other AI-related stocks and chipmakers also saw gains.

kitco.com3 min
OCT 21
$ELVMedAI 8/10

Elevance Health Reports $1.3 Billion Profit As Insurer’s Costs Ease

Elevance Health reported Q3 net income of $1.36B, up 15% YoY. Costs eased in Medicare and ACA plans, improving the benefit expense ratio. The company raised its full-year EPS outlook to $22.00 from $20.10, citing continued momentum. Elevance is the second-largest U.S. health insurer, operating Anthem Blue Cross Blue Shield plans and Medicaid services.

finance.yahoo.com2 min